MedTrace Logo

Early Warning of Delayed Cerebral Ischemia

NCT06006975 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2023-09-06

No results posted yet for this study

Summary

The goal of this observational study is to learn about the possibility to predict clinical course of subarachnoid hemorrhage (SAH) patients by performing the retrospective analysis of clinical data available in early pre-vasospasm phase.

The main questions it aims to answer are:

* What biomarkers retrieved from Computed Tomography (CT) and Computed Tomography Angiography (SAH location, leaked blood volume, cerebrospinal fluid volume, etc.) can be used to predict development of cerebral vasospasms, delayed cerebral ischemia and patients' outcome.
* What biomarkers retrieved from transcranial Doppler examinations in early pre vasospasm can be used to predict development of cerebral vasospasms, delayed cerebral ischemia and patients' outcome.
* What biomarkers retrieved from multimodal physiological monitoring in early pre vasospasm can be used to predict development of cerebral vasospasms, delayed cerebral ischemia and patients' outcome.
* What is impact of other clinical data (blood test results, age, gender, etc.) on development of cerebral vasospasms and delayed cerebral ischemia.

Conditions

  • Subarachnoid Hemorrhage, Aneurysmal
  • Vasospasm, Cerebral
  • Ischemia
  • Outcome, Fatal

Interventions

RADIATION

Computed Tomography (CT) and Computed Tomography Angiography (CTA)

CT and CTA examinations are performed as a routine procedure to evaluate SAH severity and to diagnose cerebral vasospams and delayed cerebral ischemia.

DIAGNOSTIC_TEST

Multimodal physiological monitoring

Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) measured in middle cerebral artery and heart rate. Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor.

Sponsors & Collaborators

  • Kaunas University of Technology

    collaborator OTHER

  • Lithuanian University of Health Sciences

    collaborator OTHER

  • Vilnius University

    lead OTHER

Principal Investigators

  • Saulius Rocka, Prof. Dr. · Clinic of Neurology and Neurosurgery, Faculty of Medicine, Vilnius University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-21
Primary Completion
2024-08-31
Completion
2024-12-31

Countries

  • Lithuania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06006975 on ClinicalTrials.gov